FDA’s New Labels Tell Truth about Actos Risks
Patients who take Actos (pioglitazone) should know that earlier this fall the Food and Drug Administration (FDA), the federal agency tasked with promoting and protecting public health through the regulation and supervision of pharmaceutical drugs, approved updated drug labels for pioglitazone-containing medicines. Thanks to FDA intervention, new labels must explicitly communicate that the ingestion of Actos and similar dangerous drugs for more than one year has been associated with an increased risk of bladder cancer.
Think this is the FDA’s first warning against Actos and other medications containing pioglitazone? Think again. In June of this year, in fact, the FDA intervened in the pharmaceutical market to underscore the very real risk of bladder cancer for patients taking Actos for more than one year.
Are you an Actos patient whose been diagnosed with bladder cancer? You don’t have to fight the big pharmaceutical companies alone. The dangerous drug legal experts at Fears Nachawati are prepared to fight for you. For your free consultation, call us at 1.866.545.8364 or email email@example.com. We’re ready to help.